The same is true for women with node-positive breast cancer.

In this study, mortality was infrequent but was confined to sentinel lymph node-positive patients.

Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients.

Combination adjuvant chemotherapy for node-positive breast cancer.

In one trial EST-5181, node-positive women who had already received 5 years of tamoxifen following chemotherapy were randomly assigned to continue therapy or observation.

Tamoxifen is effective in high-risk node-positive disease but not in high-risk node-negative disease.

Adjuvant radiation therapy postmastectomy in axillary node-positive tumors:

First, LMRI may play a significant role in avoiding unnecessary surgeries, that is, those in node-positive patients.

Postoperative chemoradiation therapy for patients with node-positive (T1 N1) and muscle-invasive (T2 N0) disease.

Another trial that included both node-positive and node-negative women also demonstrated the equivalence of 5 years and 10 years of therapy.

Similarly, with node-positive tumors, men increase survival using the same adjuvants as affected women, namely both chemotherapy plus tamoxifen and other hormonal therapy.

Doctors base this on a woman's prognosis and urge that she wait two years if she's node-negative and five years if she's node-positive.

Nevertheless, on the basis of this study, preoperative chemoradiation therapy has become the standard of care for patients with clinically staged T3/T4 or node-positive disease.

The CLB-8541 trial compared three dose intensities of CAF in 1,550 patients with node-positive breast cancer.

In September 2006, NICE recommended paclitaxel should not be used in the adjuvant treatment of early node-positive breast cancer.

In another study of postmenopausal women with node-positive disease, tamoxifen alone was compared with tamoxifen plus three different schedules of CMF.

Martin M, Pienkowski T, Mackey J, et al.: Adjuvant docetaxel for node-positive breast cancer.

Paik S, Bryant J, Park C, et al.: erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer.

Ragaz J, Jackson SM, Le N, et al.: Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer.

Wallgren A, Bernier J, Gelber RD, et al.: Timing of radiotherapy and chemotherapy following breast-conserving surgery for patients with node-positive breast cancer.

Of the patients assigned to the postoperative chemoradiation arm, 18% actually had pathologically determined stage I disease and were overestimated by endorectal ultrasound to have T3/T4 or node-positive disease.

Roaten JB, Partrick DA, Bensard D, et al.: Survival in sentinel lymph node-positive pediatric melanoma.

Tormey DC, Gray R, Falkson HC: Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer.

Upjohn applied for approval by the U.S. Food and Drug Administration (FDA) in node-positive breast cancer in 1984, but was turned down because of lack of data.

In 1999 Pharmacia (who had by then merged with Upjohn) received FDA approval for the use of epirubicin as a component of adjuvant therapy in node-positive patients.